WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) again urged the U.S. EPA to abandon its ethylene oxide (EtO) risk assessment value for one that is more feasible, based on the best available science and that will not potentially endanger the public health by threatening the availability of needed medical technologies.
"Anyone studying this issue can see that the EPA standard is impractical and does not meet the definition of good science," said AdvaMed President and CEO Scott Whitaker. "The medical technology industry is committed to the safe and responsible use of EtO, even as we look for alternatives and ways to reduce EtO emissions. However, the EPA's risk standard sets an unreasonable threshold that will only threaten the continued availability of tens of billions of the EtO-sterilized medical technologies patients depend on."
In comments on EPA's proposed rule on the National Emissions Standards for Hazardous Air Pollutants (NESHAP) for Miscellaneous Organic Chemical Manufacturing sources, AdvaMed argues that EPA's 2016 Integrated Risk Information System (IRIS) value for EtO should not be used for regulatory purposes. While the proposed rule does not apply to commercial sterilizers, it relies on the flawed IRIS value.
Services will be provided to healthcare facilities in NY City. Must have graduate trained, ABR, ABMP & ABSNM certified & licensed Medical Physicists in Diagnostic, Therapeutic, Nuclear Medicine & Medical Health Physics. Contact firstname.lastname@example.org
AdvaMed's full comments on the EPA proposed rule can be accessed here. Additional information on EtO and medical devices can be viewed here.
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.